Q2 2023 EPS Estimates for Catalyst Pharmaceuticals, Inc. Reduced by Analyst (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) – Research analysts at HC Wainwright lowered their Q2 2023 earnings estimates for shares of Catalyst Pharmaceuticals in a report released on Friday, May 12th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of $0.27 for the quarter, down from […]

Related Keywords

Piper Sandler ,Davids Tierney ,Insider Transactions At Catalyst Pharmaceuticals ,Millennium Management ,News Ratings For Catalyst Pharmaceuticals Daily ,Blackrock Inc ,Catalyst Pharmaceuticals ,Securities Exchange Commission ,Nasdaq ,Jupiter Asset Management Ltd ,Cantor Fitzgerald ,Catalyst Pharmaceuticals Inc ,Hedge Funds Weigh In On Catalyst Pharmaceuticals ,Catalyst Pharmaceuticals Company Profile ,Vanguard Group Inc ,Catalyst Pharmaceuticals Stock Down ,Get Rating ,Catalyst Pharmaceutical ,Truist Financial ,Pharmaceuticals Stock Down ,Street Corp ,Asset Management ,Vanguard Group ,Director David ,Exchange Commission ,Carmen Jeffrey Del ,Catalyst Pharmaceuticals Daily ,Nasdaq Cprx ,Cprx ,Medical ,Earnings Estimates ,Hc Wainwright ,